Avid Bioservices Inc (CDMO)

[cheynew]

Christopher Keenan
Vice President, Investor Relations & Corporate Communications at Depomed, Inc.
San Francisco Bay AreaBiotechnology
Previous
Peregrine Pharmaceuticals, Cytokinetics, Inc., Aradigm Corporation
Education
Kenyon College
252
connectionsSend Christopher InMailMore options
https://www.linkedin.com/in/cskeenan
Background
Summary
20 year professional of increasing responsibilities in investor relations, corporate/ financial/ internal communications, media/ public relations, corporate financing and marketing.

Skilled communicator who has executed successful investor and media relations plans for multiple companies. Clear ability to disseminate highly scientific terminology and complex concepts to mainstream audiences.

Background ranging from large to micro cap companies within the biotechnology (drug, medical device, and instrument) and pharmaceutical industries.

In previous roles, I have established the IR function and in doing so have increased sell-side coverage, attracted multiple new investors, engaged high level media opportunities, led branding/rebranding strategies, executed the company's first R&D Investor Day and rebranded the company.

Specialties: Investor surveillance/ targeting/ outreach, media/ public relations, shareholder relationship management, crisis management, road show execution, shareholder communications, marketing, corporate branding, execution of corporate marketing/ trade shows/ advertising.
Experience

Vice President, Investor Relations & Corporate Communications
Depomed, Inc.
July 2015 – Present (1 month)San Francisco Bay Area
Senior Director, Investor Relations
Peregrine Pharmaceuticals
January 2012 – June 2015 (3 years 6 months)San Francisco Bay Area
Oversaw IR and CC functions with management of two managers of Corporate Communications/ Marketing. Report to the CFO. Responsible for external and internal communications, areas of public relations, advertising and corporate marketing strategy. Serving as primary interface with current investor base as well as targeted institutional Wall Street factions.
SunriseTrial Phase 3 Clinical Trial in Advanced Lung Cancer
SunriseTrial Phase 3 Clinical Trial in Advanced Lung Cancer

Bavituximab: A Novel Immunotherapy Candidate Targeting an Upstream Immune Checkpoint to Fight Cancer
Bavituximab: A Novel Immunotherapy Candidate Targeting an Upstream Immune Checkpoint to Fight Cancer

Director, Investor and Media Relations
Cytokinetics, Inc.
October 2006 – January 2012 (5 years 4 months)South San Francisco, California
Established internal IR function. Reported to the CFO. Oversaw all investor communications including quarterly reporting, Annual Report design and execution, investor targeting and surveillance, sell-side and buy-side analyst interface, presentations to Board of Directors and all of media relations. Executed the company's first R&D Investor Day.
Director, Investor Relations & Corporate Communications
Aradigm Corporation
April 2002 – September 2006 (4 years 6 months)Hayward, California
Served as sole interface for primarily retail-held investor base. Reported to the CFO. Oversaw brainstorming and execution of all corporate communication strategies including financial announcements, IR webcasts, internal communications and media relations. Responsible for company's first print advertisement, trade shows/booth design and attendance and creation of marketing collateral material. Worked collaboratively with corporate partner Novo Nordisk.
Director, Corporate Communcations
PerkinElmer Inc.
May 2000 – February 2001 (10 months)Wellesley, Massachusetts
Served as corporate interface on CC issues for four business units (Optoelectronics, Instruments, Fluid Sciences, Life Sciences). Reported to VP of IR and Corporate Communications. Oversaw the launch and integration of what is now PerkinElmer NEN® (New England Nuclear) which provides radiochemicals, scintillation cocktails, vials, and microplates, radiometric detection instrumentation and reagent services. Secured press for CEO on multiple CNBC shows, Bloomberg News, print including features in The Boston Globe and Forbes and managed the CEO's 2000 Harvard Business Review feature.
Associate Director, Investor Relations and Corporate Communications
Isis Pharmaceuticals Inc.,
March 1997 – April 2000 (3 years 2 months)Carlsbad, California
Served as one of the intermediaries between retail and instutional shareholders as well as corporate partners and the company. Reported to the Vice President, IR and Corporate Communications. Assisted in execution of company materials including public announcements, scientific collaterial and the Annual Shareholder Scientific Forum/ Annual Meeting. Responsible for managing outside public relations firms and execution of a media relations strategy.
Senior Research Associate
The Weinberg Group
August 1990 – March 1997 (6 years 8 months)Washington D.C. Metro Area
Assisted clients in all stages of a liability crisis, from the early phases of regulatory and legislative scrutiny through the litigation battles and advising on end-stage settlement strategies. Provided research in support of complex scientific and financial issues central to resolving high-profile disputes that impacted the client's products and corporate image. These included scientific literature review and synopsis, trial expert identification and recruitment, interactions with U.S. and European regulatory bodies and the execution and management of strategic due diligence programs in response to a Consent Decree from the U.S. Department of Justice. Issues worked on involved: Alcoholic beverages, dioxins, tobacco, Lone Star Steel litigation, breast implants and multiple medical device based litigations, asbestos and food labelling and additives.

GONE BUT NOT FORGOTTEN.